MP
TLSI icon

Mangrove Partners’s TriSalus Life Sciences TLSI Stock Holding History

Mangrove Partners’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100,000
Closed -$966K – 330
2021
Q1 		$966K Buy
+100,000
New +$1.01M 0.1% 233

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Mangrove Partners's TLSI Position: Q2 2021 in Review

Mangrove Partners sold out of TriSalus Life Sciences (TLSI) in Q2 2021, closing a stake of 100,000 shares — an estimated $966K sold.

Mangrove Partners first reported a position in TLSI in Q1 2021 and held it in 1 quarter. The position peaked at $966K in Q1 2021. 53 funds tracked by Wall St. Rank hold TLSI as of Q2 2021.

  • Mangrove Partners reported no remaining TriSalus Life Sciences position as of Q2 2021 after selling out during the quarter.
  • Mangrove Partners sold 100,000 TriSalus Life Sciences shares in Q2 2021, an estimated $966K.
  • Mangrove Partners first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 1 quarter.
  • Mangrove Partners's TriSalus Life Sciences position peaked at $966K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2021.

Based on Mangrove Partners's 13F filing for Q2 2021, filed 16 Aug 2021.